Ancient herbal remedy tested to boost IVF success
NCT ID NCT04872660
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether taking Gushen Antai pills, a blend of 10 herbs, can increase the chance of an ongoing pregnancy (past 12 weeks) in women with normal ovarian reserve who are undergoing IVF. 800 women will be randomly assigned to receive either the herbal pill or a placebo. The goal is to see if this supplement improves pregnancy rates after embryo transfer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Gushen Antai Pill (a blend of 10 herbs)
- What this could lead to
- If it works, this could provide a natural supplement to boost pregnancy success in IVF.
- What could go wrong
- This is a phase 4 trial, but it's testing a traditional Chinese medicine with limited prior evidence. The placebo group helps, but results may not apply to all women.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 800 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2021
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 42 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with normal ovarian function reserve (5 ≤ AFC ≤ 15, 1.2 ng/ml ≤ AMH ≤ 3.5 ng/ml). * Patients with regular menstrual cycle (21-35 days) and normal ovulation. * Initial IVF / ICSI treatment. * At least one embryo or blastocyst available for transfer. Exclusion Criteria: * Age ≥ 43 years old. * Body mass index (BMI) ≥ 28 Kg/m2. * "Freeze-all" strategy. * Those using the natural cycle or mild stimulation for IVF/ICSI treatment. * Individuals with severe hyperstimulation ovarian syndrome during controlled ovarian stimulation. * Acceptors of donated oocytes or performed either In vitro Maturation (IVM) or blastocyst biopsy for Preimplantation Genetic Diagnosis (PGD) or Preimplantation Genetic Testing for Aneuploidies (PGT-A). * History of two or more previous consecutive spontaneous abortions. * History of two or more previous IVF-ET failures. * Karyotype abnormalities. * Polycystic ovary syndrome. * Presence of a non-surgically treated hydrosalpinx, uterine cavity fluid or endometrial polyp and an ovarian endometriosis cyst requiring surgery, during ovarian stimulation. * Congenital or acquired abnormalities of uterine anatomy. * Combined contraindications to assisted reproductive technology or pregnancy, such as uncontrolled abnormalities of liver and kidney function, diabetes mellitus (glycosylated haemoglobin ≤7%, fasting blood glucose \<10 mmol/L ), hypertension, thyroid disease, symptomatic heart disease, moderate to severe anaemia, history of malignancy or thromboembolism or propensity to thrombosis, severe psychiatric disorder, acute infections of the genitourinary system, sexually transmitted diseases, serious adverse habits such as drug abuse, exposure to teratogenic amounts of radiation, toxins, or drugs (such as prednisone or other hormones, adrenaline, antibiotics, or hypertension, cardiovascular, or antiviral medications) during the active procedure period , and uterine factor infertility or physical illness which prevents the ability to bear a pregnancy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Infertility, female are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Affiliated Hospital of Shandong University of Traditional Chinese Medicine
RECRUITINGJinan, Shandong, 250014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antioxidant supplement tested as fertility booster for PCOS
- Do infertility treatments leave a metabolic mark on children?
- Can AI learn to spot endometriosis and fibroids on ultrasound?
- One shot instead of many: a simpler path to IVF egg retrieval?
- Can sex boost the odds of IVF success?
- IVF Needle-Free? oral pill tested as injection alternative